7A40.6

ICD-11 MMS 2026-01

Central sleep apnoea due to a medication or substance

Description

Central sleep apnoea due to a medication is characterised by a pattern of recurring, predominantly central sleep apnoea or hypopnoea (more than five per hour) that is attributable to a medication or substance, most commonly long-acting opioids (e.g. methadone, long-acting morphine or oxycodone, fentanyl patches). The disturbance is sufficiently severe to cause symptoms such as daytime sleepiness, disturbed sleep, awakening with dyspnoea, or snoring. Obstructive apnoeas and hypoventilation may be present, but central sleep apnoea is the predominant finding. Note: A definitive diagnosis requires objective evidence based on polysomnography in the context of medication or substance use that is judged to be causing the symptoms.

Index terms

  • Central sleep apnoea due to a medication or substance
  • Central sleep apnoea due to substances including medications

Exclusions from above levels

  • KB2A.0 – Central neonatal apnoea
  • KB2A – Apnoea of newborn

Sibling codes

  • 7A40.0 – Primary central sleep apnoea
  • 7A40.1 – Primary central sleep apnoea of infancy
  • 7A40.2 – Primary central sleep apnoea of prematurity
  • 7A40.3 – Central sleep apnea with Cheyne-Stokes breathing
  • 7A40.4 – Central sleep apnoea due to a medical condition without Cheyne-Stokes breathing
  • 7A40.5 – Central sleep apnoea due to high-altitude periodic breathing
  • 7A40.7 – Treatment-emergent central sleep apnoea
  • 7A40.Y – Other specified central sleep apnoeas
  • 7A40.Z – Central sleep apnoeas, unspecified

Foundation entity

Central sleep apnoea due to a medication or substance – http://id.who.int/icd/entity/2012656262

Allowed postcoordination axes

Part of: 7A40: Central sleep apnoeas › 07: Sleep-wake disorders